Sentences with word «isocitrate»

Two cases harbored mutations in isocitrate dehydrogenase 2 (IDH2), a gene known to be recurrently mutated in AML, glioblastoma, and other tumors.

The persistent bacteria uses an enzyme called isocitrate lyase (ICL) as part of a metabolic pathway that breaks down fatty acids for energy.

This was where Rey and I would put Supernatural in the background and fangirl over Jensen Ackles while going over the Krebs cycle and the difference between citrate and isocitrate structures while Nadia read fanfics.

But if isocitrate goes the biosynthesis route, it must be replenished or else the energy - producing cycle will stop.

The results showed that the mycobacterium decides where to direct isocitrate by using a mechanism that is not like a simple on - off switch.

Similarly, the mechanism that controls how isocitrate is used responds to negative feedback, and so it dampens «noise» to maintain optimal levels.»

A pyruvate cycling pathway involving cytosolic NADP - dependent isocitrate dehydrogenase regulates glucose - stimulated insulin secretion.

It's particularly because components of the citric acid cycle, specifically isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have recently emerged as oncogenes that are recurrently mutated in gliomas and leukemias.

Enasidenib is the first isocitrate dehydrogenase 2 (IDH2) inhibitor approved by the FDA, indicated for adults with relapsed or refractory AML and IDH2 mutations as detected by an approved assay.

The molecule in question is called isocitrate, which, once produced, can go in two directions: continue the energy production cycle or be taken away to synthesize other parts of the bacterium.

That case became even stronger with the discovery in 2008 of a mutated gene for a metabolic enzyme called IDH (isocitrate dehydrogenase) in some leukemias, brain cancers, and gall bladder and gastrointestinal cancers.

Cells secrete 2HG when the isocitrate dehydrogenase 1 (IDH1) or IDH2 genes are mutated.

In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.

The key to controlling which route isocitrate will take seems to lie in the enzymes surrounding all these reactions: the enzyme isocitrate dehydrogenase keeps it for the fat - metabolism and energy production cycle; the enzymes isocitrate lyase and malate synthase divert it away into biosynthetic processes in the bacterium.

Each subtype was classified by gene expression clustering, and showed specific patterns of genetic alterations, particularly for four genes: platelet - derived growth factor receptor alpha (PDGFRA), isocitrate dehydrogenase 1 (IDH1), epidermal growfth factor receptor (EGFR), and neurofibromin 1 (NF1).